Picton Mahoney Asset Management’s Silexion Therapeutics Warrant SLXNW Stock Holding History

Picton Mahoney Asset Management’s Portfolio SLXNW Stock Details SLXNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.16K	Hold	57,175	–	–	﹤0.01%	1124
2025 Q4	$1.49K	Hold	57,175	–	–	﹤0.01%	1007
2025 Q3	$1K	Hold	57,175	–	–	﹤0.01%	1056
2025 Q2	$2K	Hold	57,175	–	–	﹤0.01%	718
2025 Q1	$4K	Hold	57,175	–	–	﹤0.01%	664
2024 Q4	$1K	Hold	57,175	–	–	﹤0.01%	843
2024 Q3	$3K	Buy	+57,175	New	+$3.31K	﹤0.01%	564

Other funds holding SLXNW

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

SBLIC

Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Picton Mahoney Asset Management's SLXNW Position: Q1 2026 in Review

Picton Mahoney Asset Management held its Silexion Therapeutics Warrant (SLXNW) position steady in Q1 2026 at 57,175 shares worth $1.16K. The position accounts for ﹤0.01% of the portfolio, ranked #1124.

Picton Mahoney Asset Management first reported a position in SLXNW in Q3 2024 and has held it in 7 quarters since. The position peaked at $4K in Q1 2025. 19 funds tracked by Wall St. Rank hold SLXNW as of Q1 2026.

Picton Mahoney Asset Management held 57,175 shares of Silexion Therapeutics Warrant worth $1.16K as of Q1 2026.
Picton Mahoney Asset Management left its Silexion Therapeutics Warrant share count unchanged in Q1 2026.
Silexion Therapeutics Warrant made up ﹤0.01% of Picton Mahoney Asset Management's portfolio in Q1 2026, its #1124 holding.
Picton Mahoney Asset Management first reported a position in Silexion Therapeutics Warrant in Q3 2024 and has held it in 7 quarters since.
Picton Mahoney Asset Management's Silexion Therapeutics Warrant position peaked at $4K in Q1 2025.
19 funds tracked by Wall St. Rank held Silexion Therapeutics Warrant as of Q1 2026.

Based on Picton Mahoney Asset Management's 13F filing for Q1 2026, filed 13 May 2026.